AbbVie Exercises its Option to License Agreement for BioArctic’s Alpha-Synuclein Antibody Portfolio, Signed in 2016

 AbbVie Exercises its Option to License Agreement for BioArctic’s Alpha-Synuclein Antibody Portfolio, Signed in 2016

AbbVie Exercises its Option to License Agreement for BioArctic’s Alpha-Synuclein Antibody Portfolio, Signed in 2016

Shots:

  • BioArctic to get $755M as total deal value (with upfront previously paid) and $50M milestone payments in addition to royalties on sales
  • In 2016, AbbVie and BioArctic ($80M upfront) entered into a global collaboration to develop & commercialize BioArctic’s Alpha-Synuclein Ab Platform to treat Parkinson Disease
  • BAN0805, a leading BioArctic’s Alpha-Synuclein Ab indicated for Parkinson Disease progression, while its IND is under process to onset its first clinical study in 2019

Click here to read full press release/ article | Ref: BioArctic| Image: BioSpectrum Asia

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post